Astec Lifesciences Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: May 31, 2025, 9:37 pm

Competitors of Astec Lifesciences Ltd

All Competitor Stocks of Astec Lifesciences Ltd

Quarterly Result

Last Updated: May 31, 2025, 9:46 am

Below is a detailed analysis of the quarterly data for Astec Lifesciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 120.00 Cr.. The value appears strong and on an upward trend. It has increased from 94.00 Cr. (Dec 2024) to 120.00 Cr., marking an increase of 26.00 Cr..
• For Expenses, as of Mar 2025, the value is 114.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 100.00 Cr. (Dec 2024) to 114.00 Cr., marking an increase of 14.00 Cr..
• For Operating Profit, as of Mar 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from -6.00 Cr. (Dec 2024) to 6.00 Cr., marking an increase of 12.00 Cr..
• For OPM %, as of Mar 2025, the value is 5.00%. The value appears strong and on an upward trend. It has increased from -6.00% (Dec 2024) to 5.00%, marking an increase of 11.00%.
• For Other Income, as of Mar 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Dec 2024) to 1.00 Cr., marking a decrease of 1.00 Cr..
• For Interest, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 10.00 Cr..
• For Depreciation, as of Mar 2025, the value is 12.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.00 Cr. (Dec 2024) to 12.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Mar 2025, the value is -16.00 Cr.. The value appears strong and on an upward trend. It has increased from -25.00 Cr. (Dec 2024) to -16.00 Cr., marking an increase of 9.00 Cr..
• For Tax %, as of Mar 2025, the value is 3.00%. The value appears to be improving (decreasing) as expected. It has decreased from 61.00% (Dec 2024) to 3.00%, marking a decrease of 58.00%.
• For Net Profit, as of Mar 2025, the value is -16.00 Cr.. The value appears strong and on an upward trend. It has increased from -40.00 Cr. (Dec 2024) to -16.00 Cr., marking an increase of 24.00 Cr..
• For EPS in Rs, as of Mar 2025, the value is -8.20. The value appears strong and on an upward trend. It has increased from -20.59 (Dec 2024) to -8.20, marking an increase of 12.39.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: May 3, 2025, 3:10 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: May 13, 2025, 3:51 pm

Below is a detailed analysis of the balance sheet data for Astec Lifesciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 20.00 Cr..
• For Reserves, as of Mar 2025, the value is 215.00 Cr.. The value appears to be declining and may need further review. It has decreased from 350.00 Cr. (Mar 2024) to 215.00 Cr., marking a decrease of 135.00 Cr..
• For Borrowings, as of Mar 2025, the value is 555.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 494.00 Cr. (Mar 2024) to 555.00 Cr., marking an increase of 61.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 92.00 Cr.. The value appears to be improving (decreasing). It has decreased from 112.00 Cr. (Mar 2024) to 92.00 Cr., marking a decrease of 20.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 881.00 Cr.. The value appears to be improving (decreasing). It has decreased from 975.00 Cr. (Mar 2024) to 881.00 Cr., marking a decrease of 94.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 520.00 Cr.. The value appears strong and on an upward trend. It has increased from 386.00 Cr. (Mar 2024) to 520.00 Cr., marking an increase of 134.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 165.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 165.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 361.00 Cr.. The value appears to be declining and may need further review. It has decreased from 424.00 Cr. (Mar 2024) to 361.00 Cr., marking a decrease of 63.00 Cr..
• For Total Assets, as of Mar 2025, the value is 881.00 Cr.. The value appears to be declining and may need further review. It has decreased from 975.00 Cr. (Mar 2024) to 881.00 Cr., marking a decrease of 94.00 Cr..

However, the Borrowings (555.00 Cr.) are higher than the Reserves (₹215.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Astec Lifesciences Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 24, the value is -23.93. This value is below the healthy minimum of 5. It has decreased from 13.04 (Mar 23) to -23.93, marking a decrease of 36.97.
• For Diluted EPS (Rs.), as of Mar 24, the value is -23.93. This value is below the healthy minimum of 5. It has decreased from 13.04 (Mar 23) to -23.93, marking a decrease of 36.97.
• For Cash EPS (Rs.), as of Mar 24, the value is -5.42. This value is below the healthy minimum of 3. It has decreased from 30.22 (Mar 23) to -5.42, marking a decrease of 35.64.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 188.44. It has decreased from 214.00 (Mar 23) to 188.44, marking a decrease of 25.56.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 188.44. It has decreased from 214.00 (Mar 23) to 188.44, marking a decrease of 25.56.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 233.66. It has decreased from 320.40 (Mar 23) to 233.66, marking a decrease of 86.74.
• For PBDIT / Share (Rs.), as of Mar 24, the value is -0.13. This value is below the healthy minimum of 2. It has decreased from 45.56 (Mar 23) to -0.13, marking a decrease of 45.69.
• For PBIT / Share (Rs.), as of Mar 24, the value is -18.62. This value is below the healthy minimum of 0. It has decreased from 28.39 (Mar 23) to -18.62, marking a decrease of 47.01.
• For PBT / Share (Rs.), as of Mar 24, the value is -31.49. This value is below the healthy minimum of 0. It has decreased from 17.82 (Mar 23) to -31.49, marking a decrease of 49.31.
• For Net Profit / Share (Rs.), as of Mar 24, the value is -23.91. This value is below the healthy minimum of 2. It has decreased from 13.05 (Mar 23) to -23.91, marking a decrease of 36.96.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -23.93. This value is below the healthy minimum of 2. It has decreased from 13.04 (Mar 23) to -23.93, marking a decrease of 36.97.
• For PBDIT Margin (%), as of Mar 24, the value is -0.05. This value is below the healthy minimum of 10. It has decreased from 14.21 (Mar 23) to -0.05, marking a decrease of 14.26.
• For PBIT Margin (%), as of Mar 24, the value is -7.97. This value is below the healthy minimum of 10. It has decreased from 8.86 (Mar 23) to -7.97, marking a decrease of 16.83.
• For PBT Margin (%), as of Mar 24, the value is -13.47. This value is below the healthy minimum of 10. It has decreased from 5.56 (Mar 23) to -13.47, marking a decrease of 19.03.
• For Net Profit Margin (%), as of Mar 24, the value is -10.23. This value is below the healthy minimum of 5. It has decreased from 4.07 (Mar 23) to -10.23, marking a decrease of 14.30.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is -10.24. This value is below the healthy minimum of 8. It has decreased from 4.06 (Mar 23) to -10.24, marking a decrease of 14.30.
• For Return on Networth / Equity (%), as of Mar 24, the value is -12.70. This value is below the healthy minimum of 15. It has decreased from 6.09 (Mar 23) to -12.70, marking a decrease of 18.79.
• For Return on Capital Employeed (%), as of Mar 24, the value is -6.32. This value is below the healthy minimum of 10. It has decreased from 12.28 (Mar 23) to -6.32, marking a decrease of 18.60.
• For Return On Assets (%), as of Mar 24, the value is -4.81. This value is below the healthy minimum of 5. It has decreased from 2.61 (Mar 23) to -4.81, marking a decrease of 7.42.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.53. This value is within the healthy range. It has increased from 0.02 (Mar 23) to 0.53, marking an increase of 0.51.
• For Total Debt / Equity (X), as of Mar 24, the value is 1.34. This value exceeds the healthy maximum of 1. It has increased from 0.81 (Mar 23) to 1.34, marking an increase of 0.53.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.46. It has decreased from 0.66 (Mar 23) to 0.46, marking a decrease of 0.20.
• For Current Ratio (X), as of Mar 24, the value is 1.00. This value is below the healthy minimum of 1.5. It has increased from 0.94 (Mar 23) to 1.00, marking an increase of 0.06.
• For Quick Ratio (X), as of Mar 24, the value is 0.51. This value is below the healthy minimum of 1. It has increased from 0.38 (Mar 23) to 0.51, marking an increase of 0.13.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.30. This value is below the healthy minimum of 4. It has decreased from 1.91 (Mar 23) to 1.30, marking a decrease of 0.61.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is -6.26. This value is below the healthy minimum of 20. It has decreased from 11.50 (Mar 23) to -6.26, marking a decrease of 17.76.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is -27.54. This value is below the healthy minimum of 20. It has decreased from 4.96 (Mar 23) to -27.54, marking a decrease of 32.50.
• For Earning Retention Ratio (%), as of Mar 24, the value is 106.26. This value exceeds the healthy maximum of 70. It has increased from 88.50 (Mar 23) to 106.26, marking an increase of 17.76.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 127.54. This value exceeds the healthy maximum of 70. It has increased from 95.04 (Mar 23) to 127.54, marking an increase of 32.50.
• For Interest Coverage Ratio (X), as of Mar 24, the value is -0.01. This value is below the healthy minimum of 3. It has decreased from 4.31 (Mar 23) to -0.01, marking a decrease of 4.32.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is -0.85. This value is below the healthy minimum of 3. It has decreased from 2.24 (Mar 23) to -0.85, marking a decrease of 3.09.
• For Enterprise Value (Cr.), as of Mar 24, the value is 2,574.29. It has decreased from 3,049.60 (Mar 23) to 2,574.29, marking a decrease of 475.31.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 5.62. This value exceeds the healthy maximum of 3. It has increased from 4.85 (Mar 23) to 5.62, marking an increase of 0.77.
• For EV / EBITDA (X), as of Mar 24, the value is -9,580.53. This value is below the healthy minimum of 5. It has decreased from 34.14 (Mar 23) to -9,580.53, marking a decrease of 9,614.67.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 4.55. This value exceeds the healthy maximum of 3. It has increased from 4.31 (Mar 23) to 4.55, marking an increase of 0.24.
• For Retention Ratios (%), as of Mar 24, the value is 106.26. This value exceeds the healthy maximum of 70. It has increased from 88.49 (Mar 23) to 106.26, marking an increase of 17.77.
• For Price / BV (X), as of Mar 24, the value is 5.64. This value exceeds the healthy maximum of 3. It has decreased from 6.46 (Mar 23) to 5.64, marking a decrease of 0.82.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 4.55. This value exceeds the healthy maximum of 3. It has increased from 4.31 (Mar 23) to 4.55, marking an increase of 0.24.
• For EarningsYield, as of Mar 24, the value is -0.02. This value is below the healthy minimum of 5. It has decreased from 0.01 (Mar 23) to -0.02, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness